| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7297136 | IMPAX | Medicine injection devices and methods |
Jan, 2025
(1 year, 3 months from now) | |
| US10166334 | IMPAX | Medicine injection apparatuses |
Jan, 2025
(1 year, 4 months from now) | |
| US7621891 | IMPAX | Method and apparatus for delivering epinephrine |
Feb, 2025
(1 year, 4 months from now) | |
| US7905352 | IMPAX | Kits containing medicine injection devices and containers |
Apr, 2027
(3 years from now) | |
Adrenaclick is owned by Impax.
Adrenaclick contains Epinephrine.
Adrenaclick has a total of 4 drug patents out of which 0 drug patents have expired.
Adrenaclick was authorised for market use on 30 May, 2003.
Adrenaclick is available in injectable;intramuscular, subcutaneous dosage forms.
The generics of Adrenaclick are possible to be released after 12 April, 2027.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: NA
Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENACLICK family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic